Literature DB >> 27086596

Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease.

Eun Sun Jung1,2, Kyoungbun Lee1,3, Eunsil Yu1,4, Yun Kyung Kang1,5, Mee-Yon Cho1,6, Joon Mee Kim1,7, Woo Sung Moon1,8, Jin Sook Jeong1,9, Cheol Keun Park1,10, Jae-Bok Park1,11, Dae Young Kang1,12, Jin Hee Sohn1,13, So-Young Jin1,14.   

Abstract

BACKGROUND: The histomorphologic criteria for the pathological features of liver tissue from patients with non-alcoholic fatty liver disease (NAFLD) remain subjective, causing confusion among pathologists and clinicians. In this report, we studied interobserver agreement of NAFLD pathologic features and analyzed causes of disagreement.
METHODS: Thirty-one cases of clinicopathologically diagnosed NAFLD from 10 hospitals were selected. One hematoxylin and eosin and one Masson's trichrome-stained virtual slide from each case were blindly reviewed with regard to 12 histological parameters by 13 pathologists in a gastrointestinal study group of the Korean Society of Pathologists. After the first review, we analyzed the causes of disagreement and defined detailed morphological criteria. The glass slides from each case were reviewed a second time after a consensus meeting. The degree of interobserver agreement was determined by multi-rater kappa statistics.
RESULTS: Kappa values of the first review ranged from 0.0091-0.7618. Acidophilic bodies (k = 0.7618) and portal inflammation (k = 0.5914) showed high levels of agreement, whereas microgranuloma (k = 0.0984) and microvesicular fatty change (k = 0.0091) showed low levels of agreement. After the second review, the kappa values of the four major pathological features increased from 0.3830 to 0.5638 for steatosis grade, from 0.1398 to 0.2815 for lobular inflammation, from 0.1923 to 0.3362 for ballooning degeneration, and from 0.3303 to 0.4664 for fibrosis.
CONCLUSIONS: More detailed histomorphological criteria must be defined for correct diagnosis and high interobserver agreement of NAFLD.

Entities:  

Keywords:  Interobserver agreement; Non-alcoholic fatty liver disease; Pathologic features

Year:  2016        PMID: 27086596      PMCID: PMC4876083          DOI: 10.4132/jptm.2016.03.01

Source DB:  PubMed          Journal:  J Pathol Transl Med        ISSN: 2383-7837


Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological spectrum characterized by hepatic steatosis without history of significant alcohol use or other known liver disease. The commonly associated factors include obesity, insulin resistance syndrome, and hyperlipidemia. Other associations include jejuno-ileal bypass/gastroplasty surgery for morbid obesity, parenteral nutrition, forms of malnutrition, bacterial contamination of the small bowel, certain inherited metabolic disorders, and a wide range of drugs and environmental toxins [1]. The natural history and histological spectrum of NAFLD range from stable simple steatosis to progressive or advanced disease, such as steatohepatitis, cirrhosis, and even hepatocellular carcinoma [2-13]. A clinicopathological correlation is needed to diagnose NAFLD, as clinical assessment, laboratory tests, and imaging techniques alone provide limited pertinent information. Liver biopsy is the only reliable diagnostic tool to evaluate a patient with suspected NAFLD. Degree of steatosis, liver injury, and fibrosis associated with NAFLD can be identified and differentiated from simple steatosis and nonalcoholic steatohepatitis (NASH), which is the progressive form of NAFLD [14,15]. A NAFLD histopathological grading system was proposed by Brunt et al. in 1999 [16]. They proposed to classify each of steatosis, inflammation, and ballooning degeneration into three grades and fibrosis into four stages. Since then, Kleiner et al. [17] of the NASH Clinical Research Network have proposed a more relevant classification. Other than steatosis, inflammation, and ballooning degeneration, they proposed the classification of fibrosis around the central area into three more detailed grades. Also, they scored each finding and suggested that a score greater than five indicates NASH. However, until now, classifications for NAFLD or NASH have differed depending on the researcher, and no NAFLD histopathological grading system has been standardized, causing confusion for clinicians and pathologists. Furthermore, the histomorphological criteria for NAFLD pathologic features in liver tissue remain subjective. Thus, in this study, we determined the interobserver agreement of NAFLD pathologic features between pathologists and analyzed the causes of the disagreement in order to define the histopathological features in more detail as the basis for a grading system.

MATERIALS AND METHODS

Thirty-one patients with clinically and pathologically diagnosed NAFLD from 10 hospitals (Daegu Catholic University Medical Center, Dong-A University Hospital, Samsung Medical Center, Seoul National University Hospital, Inje University Seoul Paik Hospital, Seoul St. Mary’s Hospital, Soon Chun Hyang University Seoul Hospital, Wonju Severance Christian Hospital, Inha University Hospital, Chungnam National University Hospital) were selected. Selection criteria were clinical NAFLD (nonalcoholic, serologically negative for viral and autoimmune markers, abnormal levels of liver enzymes such as aspartate aminotransferase and alanine aminotransferase) and age ≥19 years. Cirrhosis cases were included, and cases of drug and toxic injury conditions were excluded. Fifty-one liver biopsies from 10 hospitals were collected. Among them, 31 biopsies (≥1.5 cm in length and ≥16 G needle size) were selected. One hematoxylin and eosin (H&E)- and one Masson’s trichrome–stained slide were selected from each of the 31 cases. The biopsy specimens were anonymized and randomized by a researcher not involved in the study. All selected slides were scanned by a virtual slide scanning system (3DHistotech Ltd., Budapest, Hungary) at Asan Medical Center in Seoul. The following 12 NAFLD pathologic features were selected: steatosis grade, steatosis location, microvesicular steatosis, fibrosis stage, lobular inflammation, microgranuloma, large lipogranuloma, portal inflammation, ballooning degeneration, acidophilic bodies, Mallory’s hyaline, and glycogenated nuclei. Each parameter was reviewed and scored using the detailed scoring criteria shown in Table 1.
Table 1.

Pathological parameters and detailed scoring criteria of non-alcoholic fatty liver disease

Pathologic parameterCriteria for scoring
1Steatosis grade1: < 5%, 2: 5–33%, 3: 34–66%, 4: > 66%
2Steatosis location1: zone 1, 2: zone 3, 3: azonal, 4: panacinar
3Microvesicular steatosis0: absent, 1: present
4Fibrosis0: none
1A: mild, zone 3, perisinusoidal
1B: moderate, zone 3, perisinusoidal
1C: portal/periportal
2: perisinusoidal and portal/periportal
3: bridging fibrosis
4: cirrhosis
5Lobular inflammation0: no foci
1: < 2 foci per 200 × field
2: 2–4 foci per 200 × field
3: > 4 foci per 200 × field
6Microgranuloma0: absent, 1: present
7Large lipogranuloma0: absent, 1: present
8Portal inflammation0: none to minimal, 1: greater than minimal
9Ballooning0: absent, 1: few, 2: many/prominent
10Acidophilic bodies0: none to rare, 1: many
11Mallory’s hyaline0: none to rare, 1: many
12Glycogenated nuclei0: none to rare, 1: many
One H&E- and one Masson’s trichrome–stained virtual slide from each case were reviewed for the 12 parameters. Reviews were performed blindly by 13 pathologists from a gastrointestinal study group of the Korean Society of Pathologists. The degree of interobserver agreement for the first review was analyzed by multi-rater Kappa statistics. The results were shared with all 13 pathologists, and a consensus meeting was held after the first review to analyze the reasons for disagreement and to define the morphologic criteria in more detail. After the consensus meeting, a second review of the 12 pathological parameters was performed using glass slides from each of the 31 cases. The degree of interobserver agreement after the second review was analyzed by multi-rater Kappa statistics and compared with the results of the first review. The Institutional Review Board of Seoul St. Mary’s Hospital approved this study (KIRB-00562_5-001).

RESULTS

Kappa values of interobserver agreement for the first review ranged from 0.0091 to 0.7618 (Table 2). The order of agreement, according to the kappa value, was acidophilic bodies (k=0.7618), portal inflammation (k =0.5914), large lipogranuloma (k=0.4822), Mallory’s hyaline (k=0.4603), steatosis grade (k=0.3830), steatosis location (k=0.3388), fibrosis (k=0.3303), glycogenated nuclei (0.3218), ballooning degeneration (k=0.1923), lobular inflammation (0.1398), microgranuloma (0.0984), and microvesicular fatty change (0.0091). The kappa values of the four major pathologic features (steatosis grade, portal inflammation, ballooning degeneration, and fibrosis) were measured as 0.3829, 0.5913, 0.1923, and 0.3303, respectively. In particular, ballooning degeneration (k=0.1923), which is an important feature for diagnosis of NASH, showed a low level of agreement.
Table 2.

Comparison of kappa values after the first and second reviews of non-alcoholic fatty liver disease pathological features

Pathologic parametersFirst reviewSecond review
1Steatosis grade0.38300.5638
2Steatosis location0.33880.4502
3Microvesicular steatosis0.00910.2916
4Fibrosis0.33030.4664
5Lobular inflammation0.13980.2815
6Microgranuloma0.09840.1199
7Large lipogranuloma0.48220.5004
8Portal inflammation0.59140.7386
9Ballooning0.19230.3362
10Acidophilic bodies0.76180.6493
11Mallory's hyaline0.46030.5236
12Glycogenated nuclei0.32180.3846
Kappa values of interobserver agreement for the second review ranged from 0.1199 to 0.7386 (Table 2). The order of kappa values for interobserver agreement after the second review were portal inflammation (k=0.7386), acidophilic bodies (k=0.6493), steatosis grade (k=0.5638), Mallory’s hyaline (k=0.5236), large lipogranuloma (k=0.5004), fibrosis (k=0.4664), steatosis location (k=0.4502), glycogenated nuclei (k=0.3846), ballooning degeneration (k=0.3362), microvesicular fatty change (k=0.2916), lobular inflammation (k=0.2815), and microgranuloma (k=0.1199). The kappa values of interobserver agreement increased for all parameters except acidophilic bodies. Microvesicular steatosis demonstrated the largest improvement (k=0.0091 to 0.2916), and microgranuloma the smallest (k=0.0984 to 0.1199). All kappa values of the four major pathological features increased as follows: steatosis grade from k=0.3830 to 0.5638, portal inflammation from k=0.5914 to 0.7386, ballooning degeneration from k=0.1923 to 0.3362, and fibrosis from k=0.3303 to 0.4664.

DISCUSSION

Since the first description of NASH by Ludwig et al. in 1980 [18], several NAFLD scoring schemes have been proposed [16,17,19,20]. Among them, the NAFLD activity score (NAS) proposed by Kleiner et al. [17] is the most well-known and popular system. Their proposed NAS system is based on agreement data and a multiple regression analysis of the [14] histological features of steatosis grade, steatosis location, microvesicular steatosis, fibrosis, lobular inflammation, microgranuloma, large lipogranuloma, portal inflammation, ballooning degeneration, acidophilic bodies, pigmented macrophages, megamitochondria, Mallory’s hyaline, and glycogenated nuclei. The NAS is defined as the unweighted sum of the scores for steatosis (0–3), lobular inflammation (0–3), and ballooning (0–2) and ranges from 0 to 8. Fibrosis was not included as an NAS component. Kleiner et al. [17] reported that the interobserver agreement values for the four major features were 0.79 for steatosis grade, 0.45 for lobular inflammation, 0.56 for ballooning degeneration, and 0.84 for fibrosis. The agreement for other histologic features ranged from k=0.15 to 0.58. However, the histomorphological features of some parameters remain ambiguous, contributing to low interobserver agreement. We studied interobserver agreement among 13 pathologists for each of the 12 well-known parameters and analyzed the reasons for disagreement. At the first circulation of slides, we reviewed each case without consensus to identify current discrepancies in diagnostic criteria. The kappa values in this review ranged widely from 0.0091 to 0.7618. Kappa values of the four major pathological features at the first review were 0.3830 for steatosis grade, 0.1398 for lobular inflammation, 0.1923 for ballooning degeneration, and 0.3303 for fibrosis, lower than those of Kleiner et al. [17]. After the first review, we discussed several points of debate surrounding the definition of each parameter. As a result, we identified several details regarding steatosis grade, lobular inflammation, ballooning degeneration, fibrosis, Mallory’s body, and microvesicular fatty change and recommend the following: (1) Steatosis grade: steatosis grade should be determined by fat volume rather than the number of fatty hepatocytes at 100×optical magnification (Fig. 1).
Fig. 1.

Grading of steatosis. It is determined by fat volume rather than number of fatty hepatocytes. (A) <5%. (B) 5%–33%. (C) 34%–66%. (D) > 66%.

(2) Lobular inflammation: lobular inflammation should be graded under 200× magnification throughout the entire biopsy field, and the mean, not the maximum number in the most active field, should be determined. Spotty necrosis of hepatocytes, lymphocyte aggregations, and acidophilic bodes should be included, whereas lipogranuloma resulting from fat phagocytosis should be excluded as in the histomorphologic criteria for chronic hepatitis grading (Fig. 2).
Fig. 2.

Lobular inflammation. A focus spotty necrosis of hepatocytes (arrows), lymphocyte aggregation (arrowheads), and acidophilic bodies (asterisk) can be seen.

(3) Ballooning degeneration: the histomorphological criteria of ballooning degeneration are enlarged round cells with loss of polygonal features and cytoplasm showing heterogeneous granular features (Fig. 3). Hydropic swelling and microvesicular fatty changes should be carefully distinguished from ballooning degeneration. In cases of hydropic swelling, the hepatocyte has large, swollen, and homogenously granular cytoplasm with well-preserved polygonal features. In particular, microvesicular fatty changes can also be enlarged and can be confused with ballooning degeneration. Microvesicular fatty changes show centrally located nuclei indented by a small fat droplet with a lipoblast-like feature (Fig. 4). When only one or two ballooned cells can be seen throughout the entire field, the term “few” can be applied.
Fig. 3.

Ballooning degeneration. (A) Group of enlarged round cells with loss of polygonal features and heterogeneous granular cytoplasm are noted. (B) Ballooning degeneration with cytoplasmic Mallory’s bodies (arrows) are found.

Fig. 4.

Mimickers of ballooning degeneration. (A, B) Hydropic swelling and microvesicular fatty changes mimicking ballooning degeneration.

(4) Fibrosis: mild fibrosis should be carefully distinguished from the normal framework around the central area. Only obvious fibrosis with pericellular collagen deposition should be considered as existence of fibrosis (Fig. 5).
Fig. 5.

Fibrosis around the central area (A), normal framework (B), normal range framework without pericelluar collagen deposition (C), and mild perisinusoidal fibrosis with definite pericellular collagen deposition.

(5) Mallory’s body: Mallory’s body should be defined as a definite eosinophilic lump in the cytoplasm (Fig. 3B). (6) Microvesicular fatty changes: these are defined as lipoblast-like features showing centrally located nucleus and numerous intracytoplasmic micro-fat vacuoles inducing nuclear indentation. Microvesicular fatty changes should be carefully differentiated from cells having small- or medium-sized fat vacuoles without cytoplasmic enlargement and nuclear indentation, as mentioned by Yeh and Brunt (Fig. 6) [21].
Fig. 6.

Microvesicular steatosis. (A) Microvesicular fatty changes including lipoblast-like features showing numerous intracytoplasmic micro-fat vacuoles with nuclear indentation (arrows). (B) Excluding small- or medium-sized fat vacuoles without cytoplasmic enlargement and nuclear indentation should not be confused with microvesicular steatosis.

All kappa values increased in the second review based on the above criteria. In particular, kappa values for the four major parameters increased from 0.3830 to 0.5638 for steatosis grade, from 0.1398 to 0.2815 for lobular inflammation, from 0.1923 to 0.3362 for ballooning degeneration, and from 0.3303 to 0.4664 for fibrosis. This increased agreement likely resulted from the consensus meeting and the determination of more detailed histomorphologic criteria. However, the method used in the second review is more familiar to most pathologists and may have also contributed to increased agreement. Despite the differences in review method (virtual vs glass), there is no doubt that the exact histomorphologic criteria of NAFLD remain ambiguous and contribute to low interobserver agreement between pathologists. Therefore, our more detailed suggestions for NAFLD histomorphologic criteria—including steatosis grade, lobular inflammation, ballooning degeneration, and fibrosis, as mentioned above—will increase the accuracy of diagnosis and grading of NAFLD and improve interobserver agreement. Through this work and recommendations, we expect that a more exact basis for research of NAFLD and development of a new grading and scoring system will follow.
  21 in total

1.  A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

Review 2.  Pathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03-02       Impact factor: 46.802

3.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

4.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

5.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

Authors:  Leon A Adams; Schuyler Sanderson; Keith D Lindor; Paul Angulo
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

6.  Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.

Authors:  Christine Carter-Kent; Lisa M Yerian; Elizabeth M Brunt; Paul Angulo; Rohit Kohli; Simon C Ling; Stavra A Xanthakos; Peter F Whitington; Phunchai Charatcharoenwitthaya; Jason Yap; Rocio Lopez; Arthur J McCullough; Ariel E Feldstein
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

7.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

Authors:  Kittichai Promrat; Glen Lutchman; Gabriel I Uwaifo; Renee J Freedman; Alejandro Soza; Theo Heller; Edward Doo; Marc Ghany; Ahalya Premkumar; Yoon Park; T Jake Liang; Jack A Yanovski; David E Kleiner; Jay H Hoofnagle
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

8.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

Authors:  J Ludwig; T R Viggiano; D B McGill; B J Oh
Journal:  Mayo Clin Proc       Date:  1980-07       Impact factor: 7.616

Review 9.  Epidemiology and natural history of NAFLD and NASH.

Authors:  Janus P Ong; Zobair M Younossi
Journal:  Clin Liver Dis       Date:  2007-02       Impact factor: 6.126

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  8 in total

1.  Feasibility and agreement of stiffness measurements using gradient-echo and spin-echo MR elastography sequences in unselected patients undergoing liver MRI.

Authors:  Guilherme Moura Cunha; Kevin J Glaser; Anke Bergman; Rodrigo P Luz; Eduardo H de Figueiredo; Flavia Paiva Proença Lobo Lopes
Journal:  Br J Radiol       Date:  2018-05-17       Impact factor: 3.039

2.  Magnetic resonance elastography SE-EPI vs GRE sequences at 3T in a pediatric population with liver disease.

Authors:  Juan S Calle-Toro; Suraj D Serai; Erum A Hartung; David J Goldberg; Bradley D Bolster; Kassa Darge; Sudha A Anupindi
Journal:  Abdom Radiol (NY)       Date:  2019-03

3.  Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.

Authors:  Rish K Pai; David E Kleiner; John Hart; Oyedele A Adeyi; Andrew D Clouston; Cynthia A Behling; Dhanpat Jain; Sanjay Kakar; Mayur Brahmania; Lawrence Burgart; Kenneth P Batts; Mark A Valasek; Michael S Torbenson; Maha Guindi; Hanlin L Wang; Veeral Ajmera; Leon A Adams; Claire E Parker; Brian G Feagan; Rohit Loomba; Vipul Jairath
Journal:  Aliment Pharmacol Ther       Date:  2019-10-03       Impact factor: 8.171

4.  Non-alcoholic fatty liver disease--a chronic disease of the 21<sup>st</sup> century.

Authors:  Peter Metrakos; Tommy Nilsson
Journal:  J Biomed Res       Date:  2018-09-29

5.  Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Pik Eu Chang; George Boon Bee Goh; Wei Qiang Leow; Liang Shen; Kiat Hon Lim; Chee Kiat Tan
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

6.  Improved pathology reporting in NAFLD/NASH for clinical trials.

Authors:  Caitlin Rose Langford; Marc H Goldinger; Darren Treanor; Clare McGenity; Jonathan R Dillman; Daniela S Allende; Robert Goldin; Elizabeth M Brunt; Kurt Zatloukal; Helmut Denk; Kenneth A Fleming
Journal:  J Clin Pathol       Date:  2021-11-09       Impact factor: 3.411

7.  Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study.

Authors:  Takuya Kuwashiro; Hirokazu Takahashi; Hideyuki Hyogo; Yuji Ogawa; Kento Imajo; Masato Yoneda; Takashi Nakahara; Satoshi Oeda; Kenichi Tanaka; Yuichiro Amano; Shinji Ogawa; Atsushi Kawaguchi; Shinichi Aishima; Masayoshi Kage; Kazuaki Chayama; Atsushi Nakajima; Yuichiro Eguchi
Journal:  JGH Open       Date:  2019-12-17

8.  Deep learning quantification of percent steatosis in donor liver biopsy frozen sections.

Authors:  Lulu Sun; Jon N Marsh; Matthew K Matlock; Ling Chen; Joseph P Gaut; Elizabeth M Brunt; S Joshua Swamidass; Ta-Chiang Liu
Journal:  EBioMedicine       Date:  2020-09-24       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.